Oncology

ASCO 2020 virtual annual meeting - day 1

Our live coverage from this year’s slimmed down, virtual version of the American Society of Clinical Oncology (ASCO) annual meeting begins at 8am (ET).

News

Roche signs up with Oncimmune to explore immunotherapy respo...

Roche has doubled down on a partnership with UK biotech Oncimmune looking at how autoantibodies can affect patients’ clinical response to cancer immunotherapies.

Partner Content

Partner Content

J+D FORECASTING ANNOUNCE AN UPGRADE AND AN EXTENSION

J+D announce an upgrade and an extension to FC+

Events

JAK Inhibitors Drug Development - Digital Summit

Partner Content

Hit the JAK-pot in global race to treat COVID-19

News

There are three types of white blood cells. T lymphocytes, B lymphocytes and natural killer cells.

Kadmon preps filing for GVHD drug belumosudil after phase 3 ...

New York biotech Kadmon is on course to file for FDA approval of belumosudil for chronic graft versus host disease (GVHD) after it hit the mark in a pivotal trial.

News

AZ/Merck & Co take on Clovis as FDA approves prostate cancer...

The FDA has approved AstraZeneca and Merck & Co’s Lynparza (olaparib) in metastatic castration-resistant prostate cancer, just days after the regulator gave the nod for Clovis’ PARP-cla

ASCO 2020 virtual annual meeting - day 1

Roche signs up with Oncimmune to explore immunotherapy respo...

J+D FORECASTING ANNOUNCE AN UPGRADE AND AN EXTENSION

Hit the JAK-pot in global race to treat COVID-19

Kadmon preps filing for GVHD drug belumosudil after phase 3 ...

AZ/Merck & Co take on Clovis as FDA approves prostate cancer...

MSD takes a $400m bite of SciBrunch's KRAS drug

Discover a new era of healthcare panel engagement: Grounded ...

Oncology

Editor's Picks